A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 22 Dec 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms Bydureon
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 19 Dec 2016 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Planned number of patients changed from 110 to 115.